Invuity, Inc. (NASDAQ:IVTY)‘s stock had its “buy” rating restated by Piper Jaffray Companies in a report issued on Friday. They presently have a $12.00 price target on the medical instruments supplier’s stock. Piper Jaffray Companies’ price objective indicates a potential upside of 42.01% from the stock’s previous close.

IVTY has been the subject of several other research reports. Zacks Investment Research downgraded shares of Invuity from a “hold” rating to a “sell” rating in a research note on Thursday, September 28th. ValuEngine raised shares of Invuity from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Finally, Northland Securities reissued a “buy” rating and issued a $13.00 target price on shares of Invuity in a research note on Tuesday, September 26th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $11.67.

Invuity (NASDAQ:IVTY) opened at $8.45 on Friday. Invuity has a one year low of $5.70 and a one year high of $9.70. The company has a debt-to-equity ratio of 5.39, a current ratio of 2.90 and a quick ratio of 2.63.

Invuity (NASDAQ:IVTY) last announced its earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.04. Invuity had a negative net margin of 111.43% and a negative return on equity of 212.38%. The firm had revenue of $9.60 million during the quarter, compared to the consensus estimate of $9.87 million. equities analysts forecast that Invuity will post -2.4 EPS for the current fiscal year.

WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/11/11/invuity-inc-ivty-rating-reiterated-by-piper-jaffray-companies.html.

Institutional investors and hedge funds have recently bought and sold shares of the business. UBS Group AG grew its holdings in Invuity by 53.4% in the 1st quarter. UBS Group AG now owns 13,200 shares of the medical instruments supplier’s stock valued at $105,000 after buying an additional 4,594 shares during the period. Citadel Advisors LLC purchased a new stake in Invuity in the 2nd quarter valued at about $101,000. Renaissance Technologies LLC purchased a new stake in Invuity in the 1st quarter valued at about $151,000. Spark Investment Management LLC purchased a new stake in Invuity in the 2nd quarter valued at about $158,000. Finally, Boston Advisors LLC grew its holdings in Invuity by 55.6% in the 2nd quarter. Boston Advisors LLC now owns 28,280 shares of the medical instruments supplier’s stock valued at $205,000 after buying an additional 10,111 shares during the period. Institutional investors own 66.01% of the company’s stock.

About Invuity

Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.

Receive News & Stock Ratings for Invuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity Inc. and related stocks with our FREE daily email newsletter.